Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.
The intermediary stage between normal cognition and mild dementia is often referred to as mild cognitive impairment (MCI). 1 It is a heterogeneous clinical condition with several subtypes and multiple etiologies. [1] [2] [3] The amnestic subtype, which shows the least reversion to normal, is defined as a significant impairment in memory with no impairment in activities of daily living. 1 As many as 80% of patients with amnestic MCI progress to AD within 6 years of diagnosis. 1 In an interventional study of patients meeting Petersen criteria for amnestic MCI, 1 16% progressed to dementia per year, 99% of whom received an AD diagnosis. 4 This observation is consistent with the finding that amnestic MCI is often a degenerative condition that may represent prodromal AD. 5, 6 If this is the case, AD treatments could benefit individuals with amnestic MCI.
The acetylcholinesterase inhibitors (ChEIs) galantamine and rivastigmine are indicated for mild to moderate AD, and donepezil is indicated for mild, moderate, and severe AD. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Five ChEI trials have been performed in MCI patients. 4, [17] [18] [19] Although none of the trials met their primary efficacy objectives, positive effects on some of the secondary endpoints for cognition and function were noted for galantamine and donepezil. 4, 18, 19 Donepezil delayed progression to AD over a period of 1 year, 4 and in a separate study showed significant improvement on a modified ADAS-cog. 19 Based on these observations, the current study was designed to investigate the effect of 48 weeks of donepezil treatment on amnestic MCI in a randomized, double-blind, placebo-controlled study.
METHODS Patient population. We enrolled generally healthy, ambulatory or ambulatory-aided amnestic subjects with MCI, 45 to 90 years old, who expressed a memory complaint representing a change from previous functioning. The memory component was corroborated by an informant, and confirmed by neuropsychological testing scores: global Clinical Dementia Rating (CDR) score of 0.5 at screening with the Memory Box score of 0.5 or 1.0, with no more than two other box scores rated as high as 1.0, and no box score Ͼ1.0; Mini-Mental State Examination (MMSE) score 24 -28 inclusive (or 24 -30 before protocol amendment; based on results from the 3-year MCI trial, it was believed that more cognitively impaired patients would have a greater placebo decline on measures of cognition and global function, therefore the MMSE range was limited to 24 -28); Logical Memory II Delayed Paragraph Recall subtest of the Wechsler Memory Scale-Revised score Յ8 (16 or more years of education), Յ4 (8 -15 years of education), or Յ2 (0 -7 years of education); and Rosen modified Hachinski Ischemia scale score Յ4. These operationalized Petersen criteria are largely consistent with those used in previous donepezil MCI studies. 4, 19 All subjects had an informant with whom they had daily contact who could observe possible adverse events and accompany the subject to all visits. We also required a CT scan or MRI study within 12 months of screening showing no clinical evidence of infection, infarction, other focal lesions, or clinically significant comorbid pathologies.
Subjects were excluded if they had a diagnosis of probable or possible vascular dementia (National Institute of Neurological and Communicative Diseases and Stroke-AD and Related Disorders Association, DSM-IV criteria); another form of dementia; a neurologic or psychiatric disorder; a sleep disorder that could affect cognitive performance; drug or alcohol abuse or dependence within the previous 5 years; uncontrolled hypertension regardless of antihypertensive medication; uncontrolled diabetes mellitus; or any other medical condition deemed incompatible with study participation. Past treatment with a ChEI or memantine for Ͼ1 month or within 3 months of screening was not permitted. Patients taking concomitant anticholinergics, anticonvulsants, antiparkinsonian agents, stimulants, cholinergic agents, antipsychotics, or antidepressants or anxiolytics with anticholinergic or procholinergic effects were excluded. Study design. In this multicenter, double-blind, randomized, placebo-controlled, parallel design trial, consenting subjects who met study criteria were enrolled in a 3-week single-blind placebo run-in period followed by a 48-week double-blind period during which subjects were assigned to treatment with donepezil (5 mg/ day for 6 weeks followed by 10 mg/day) or placebo, in coded containers, according to a computerized randomization schedule generated by BlisTech Corp. Study visits took place at screening, week 3 (randomization and placebo run-in), week 0 (start of active treatment period and baseline measurements), weeks 6, 12, 24, and 36, and week 48 (study end). Donepezil hydrochloride (Aricept) was supplied by Eisai, Inc. Subjects, investigators, and sponsors were blinded to treatment allocation.
This study was conducted in accordance with the principles of the Declaration of Helsinki and with the laws and regulations of the locality in which the research was conducted. The study protocol was approved by the Institutional Review Board of each site.
Efficacy measurements. The primary efficacy measures were the modified AD Assessment Scale-cognitive subscale (ADAS-Cog) and the CDR sum of boxes (CDR-SB). The modified ADAS-Cog is an 89-point scale consisting of 13 subtests that evaluate various cognitive domains. Higher total scores indicate greater impairment. Modifications from the original test 20 include the use of 12 words in the Word Recall test rather than 10, addition of Delayed Word Recall, reduction in the number of trials for the Word Recognition Test from three to one, and addition of a concentration or distractibility item.
The CDR, which is based on a semi-structured interview with the informant and subject, measures dementia severity through six domains (each rated 0 -3, including 0.5) assessing cognition and function. Higher scores indicate greater severity. A sum of the boxes score (CDR-SB, range 0 -18) was obtained by summing the scores of each domain.
The secondary efficacy measures evaluated cognition, behavior, and function. The Symbol Digit Modalities Test (SDMT, range 0 -110) and MMSE (range 0 -30) assess cognition. The Digit Span Backwards test (DSB, range 0 -12) is a short-term memory and attention test. The Neuropsychiatric Inventory (NPI) is a 12-item scale (range 0 -144) assessing behavioral disturbances. The Perceived Deficits Questionnaire (PDQ; range 0 -80) is a subject self-assessment rating scale originally designed to assess subjective cognitive problems in multiple sclerosis. It includes 20 items assessing attention, retrospective memory, planning, and organization skills, each of which are rated on a 5-point Likert scale from 0 (never affected) to 5 (always affected). The PDQ for Relatives (PDQ-R; range 0 -80) is administered to informants regarding the subject's cognitive function. Increases in scores represent improvement for the SDMT, DSB, and MMSE, and worsening for the PDQ, PDQ-R, and NPI. The Alzheimer's Disease Cooperative Study (ADCS) Clinical Global Impression of Change-Mild Cognitive Impairment (CGIC-MCI) is a semi-structured interview in which the clinician rates global change from baseline from 1 (marked improvement) to 7 (marked worsening). The original ADCS-CGIC 21 was modified by the ADCS Group for use in MCI subjects. 4 The Patient Global Assessment (PGA) is an unstructured patient selfassessment in which subjects rate overall change in memory from 1 (very much improved) to 7 (very much worse).
The modified ADAS-Cog, CDR-SB, SDMT, DSB, and CGIC-MCI were administered at screening, week 3 (except CDR-SB and CGIC-MCI), and weeks 0, 6, 12, 24, 36, and 48. The MMSE was administered at screening, week 0, and week 48. The NPI, PDQ, and PDQ-R were administered at weeks 0, 24, and 48. The PGA was administered at weeks 6, 12, 24, 36, and 48. Safety assessment. Adverse experiences were recorded at each study visit and are presented according to Medical Dictionary for Regulatory Activities (MedDRA) terminology. Investigators were asked to evaluate severity (mild, moderate, or severe), relationship to study drug (not related, possible, or probable), and seriousness of the event. A serious adverse event was defined as any untoward medical occurrence which resulted in death, was life threatening, required or prolonged inpatient hospitalization, or resulted in persistent or significant disability/incapacity.
Statistics. Y. Sun and Y. Xu conducted the statistical analysis.
The primary efficacy analysis was a between-group comparison of the changes from baseline in total modified ADAS-cog and total CDR-SB scores. To declare the trial successful for efficacy, both variables needed to be significant. The primary and secondary analyses were performed in the intent-to-treat (ITT) population, which was defined as all subjects who received at least one dose of double-blind medication, had a baseline evaluation, and had at least one evaluation after the start of the double-blind treatment. Last observations were carried forward (LOCF) in the endpoint analyses. The safety population consisted of all subjects who took at least one dose of study medication.
Analysis of covariance with adjustments for location (US state), age, treatment, screening MMSE category (Յ28 or Ն29), and baseline value was performed for the primary variables. Significance for all tests was set at ␣ ϭ 0.05, two-tailed. All statistical analyses were performed using SAS version 6.12 or higher.
Power calculations. Based on previous findings and an expected 10% discontinuation rate before efficacy evaluation, a study population of 800 was estimated to provide 80% power to detect a 1.5-point difference on the modified ADAS-Cog and a 0.25-point difference on the CDR-SB between the placebo and donepezil groups (␣ ϭ 0.05, two-sided test).
RESULTS
The study was conducted between December 2003 and March 2007. Of 2,037 subjects screened (74 US sites), 821 were randomized to donepezil (409) or placebo (412) (figure 1). The safety population included 391 donepezil-and 387 placebo-treated subjects. Reasons for exclusion from the safety population were adverse event (7) , request of subject, investigator, or sponsor (8), medication noncompliance (1), protocol violation (5), withdrawal of consent (13) , loss to follow-up (3), or other reason (6) . The ITT population included 379 donepezil-and 378 placebo-treated subjects. A total of 226 donepezil-treated and 273 placebo-treated subjects completed the study. Main reasons for premature discontinuation or withdrawal were adverse events (72 donepezil; 32 placebo) and withdrawal of consent (42 donepezil; 33 placebo). The most frequent adverse events leading to study discontinuation or withdrawal were diarrhea (20 donepezil; 2 placebo), muscle spasms (9 donepezil; 1 placebo), and insomnia (8 donepezil; 3 placebo). The treatment groups had similar baseline characteristics (table 1): mean age overall was 70 Ϯ 10 years, and subjects were predominantly white (87%) and married (69%). Mean exposure to treatment was 248 Ϯ 120 days for donepezil and 282 Ϯ 100 days for placebo. At study end, the mean compliance of 96% was similar between treatment groups. APOE genotype (APOE4 testing), which started late, after a protocol amendment, was collected in 541 subjects. Of those subjects, 42% were APOE4 positive, with similar percentages in both groups.
Efficacy. Mean baseline modified ADAS-cog scores were 18.3 Ϯ 6.6 in the donepezil group and 18.2 Ϯ 7.0 in the placebo group. Mean baseline CDR-SB scores were 1.5 Ϯ 0.9 in both groups (table 2) .
At study endpoint, the difference between treatment groups on the modified ADAS-Cog score (Ϫ0.90 [SE, 0.37]) was small and favored donepezil (p ϭ 0.01; figure 2A) ; scores for both groups improved but the initial placebo effect was lost for the untreated group. Changes from baseline in CDR-SB scores were minimal in each group and were not significantly different between treatment groups at any time point ( figure 2B ). When modified ADAS-Cog data were stratified by APOE4 genotype, no differences between treatment groups were found in either APOE4-positive or APOE4-negative subjects (data not shown).
Overall, few significant differences were observed for the secondary variables, and there was a tendency for both groups to improve on several measures (table 2). Scores on the CGIC-MCI favored donepezil only at week 6 (p ϭ 0.04); scores on the PGA favored APOE4 genotyping was introduced as a protocol amendment after the start of the study. The test, though scheduled for week Ϫ3, was also allowed at any other visit or at an unscheduled visit if necessary. *Donepezil, n ϭ 262; placebo, n ϭ 279. (table 3) . The most frequent treatmentemergent adverse events in the donepezil group were diarrhea (16.4%), muscle spasms (13.3%), and nausea (9.7%). Most adverse events were mild or moderate. Adverse events rated possibly or probably related to study medication had a higher incidence in the donepezil group (35.5% possibly related and 11.8% probably related) than in the placebo group (23.0% possibly related and 2.3% probably related). The most frequent treatment-emergent adverse events assessed as probably related to study medication in the donepezil group were diarrhea (3.8%), nausea (2.6%), and abnormal dreams (2.6%). Eleven percent of subjects in each treatment group experienced a severe adverse event. The only treatment-emergent adverse event reported as severe for Ն1% of subjects in either treatment group was coronary artery disease, which was reported as severe for 5 placebo subjects (1.3% of the placebo group). Serious adverse events were reported in 48 (12.3%) donepezil-treated subjects and 41 (10.6%) placebotreated subjects. The only serious adverse events reported for Ն1% of subjects in either treatment group were syncope (4 donepezil; 1 placebo) and coronary artery disease (0 donepezil; 5 placebo). Four deaths occurred (3 donepezil; 1 placebo). In the donepezil group, the three deaths were attributed to lymphoma, sudden death, and lung cancer. In the placebo group, the death was attributed to pleural mesothelioma. All deaths were assessed by the investigator as not related to study medication. DISCUSSION In this 48-week, randomized, doubleblind, placebo-controlled trial, subjects with amnestic MCI who were treated with donepezil 10 mg did not perform better than placebo-treated subjects on the dual primary outcomes. A small, significant benefit was seen on the modified ADAS-cog, but not on the CDR-SB. Insensitivity of the outcome measures to change over the course of a year and a tendency for a placebo response in the untreated group may have contributed to the negative results. Overall, donepezil was well tolerated, although adverse events and discontinuation rates due to adverse events were higher in the donepezil group than in the placebo group, as expected. Values are n (%) of subjects. *Recorded in Ͼ5.0% of patients in the donepezil group and with a two times greater rate in the donepezil group than the placebo group.
Examination of the secondary outcomes leads to the observation that donepezil-treated amnestic MCI subjects subjectively rated themselves as better. Consistent with this observation, informants of untreated patients rated them as worse compared to the observations of informants of treated subjects. One hypothesis generated by the current study is that most of the standardized outcome measures were not sensitive enough to treatment benefits in this minimally impaired population.
Although donepezil and galantamine have shown clear efficacy in cognition and function in mild AD, 22, 23 multiple studies have not supported the same degree of benefit for ChEIs in amnestic MCI. 4, [17] [18] [19] All three donepezil trials for MCI showed significant benefit on the ADAS-cog over 6 to 12 months but no benefit on the modified CGIC-MCI or CDR-SB. These data could be interpreted to mean that ChEIs are not clinically effective in the treatment of amnestic MCI despite widespread belief that amnestic MCI represents a very mild, prodromal stage of AD. Another contributing factor is that all of these studies relied on objective instruments that were developed for AD and not specifically for MCI, such as the CDR, which may not be sufficiently sensitive to detect subtle changes in cognition and function at a stage of disease when decline is very mild and progressing slowly. 24, 25 To this point, a relatively young and mildly impaired patient population was enrolled in the present study; subjects in this study were approximately 3 years younger than those in the ADCS MCI trial 4 and 2 years younger than subjects in the 24-week donepezil MCI trial. 19 The publicity regarding potential benefits of ChEIs for MCI may have discouraged more impaired MCI subjects from participating in this trial, producing a milder MCI cohort less likely to respond to ChEIs. In contrast to the modest treatment difference we observed on the modified ADAS-cog in this 48-week study, in the 24-week trial the modified ADAS-cog favored donepezil with a treatment difference of 1.9 points.
Subjects with MCI may also differ from patients with AD in other substantial ways. For example, one study showed cholinergic sprouting in the cortex of subjects with MCI that was not seen in subjects with AD and there may be less cholinergic dysfunction in the MCI stage of AD. 26, 27 Thus, stage-related neuronal and neurochemical differences may also account for the failure to see the same degree of benefits with ChEIs in subjects with amnestic MCI.
Newer MCI-specific instruments may show greater sensitivity to change in MCI. 28 Additionally, new instruments are needed that sensitively measure functional change in complex activities in subjects with MCI. By definition, the baseline functional im-pairment in these subjects with MCI was minimal. It is not surprising that there was no difference on the CDR-SB, as functional differences are factored in to several of the box scores. However, subjects themselves detected significant improvement in cognition and global performance. Future MCI trials should utilize more sensitive primary outcome measures, such as measures of complex daily functioning, performance-based measures, or study designs to show retention of memory or other cognitive abilities in treated patients over time compared to loss of these skills in placebo-treated subjects. Cognitive scores consistently improve over time in MCI trials, suggesting a learning effect that also needs to be factored into the design of future MCI studies.
Because MCI symptoms are mild compared to AD, the safety and tolerability of treatment must be quite good to yield a favorable risk-benefit assessment. Discontinuation rates in treated subjects due to adverse events were higher (ϳ18%) than those reported in mild to moderate and moderate to severe AD donepezil trials (Ͻ10%) despite similar overall adverse event rates (ϳ80%). 16, 29 These data suggest that patients with MCI may be less willing or less able to tolerate the side effects of ChEI treatment than patients with more advanced symptoms, or that they are less likely to forget to report adverse events. Nonetheless, adverse events were generally mild or moderate and few serious drug-related adverse events occurred.
MCI studies with Cox-2 inhibitors (rofecoxib) and nootropics (piracetam) have also been negative. 30, 31 In a rofecoxib trial, conversion rates were lower in the placebo group than in the rofecoxib group and scores on secondary measures of cognition and function were similar between groups. 31 In a piracetam trial, no significant differences between piracetam and placebo treatment were noted for either primary or secondary variables. 30 Taken together, therapeutic studies for amnestic MCI suggest that the benefits of interventions may be stage-specific. Additionally, considerable refinement may be needed for MCI clinical trial designs. While effectiveness of donepezil and other ChEIs has been demonstrated in the mildest stages of AD, the evidence is currently inconclusive with regard to the benefits of treating patients with amnestic MCI with available antidementia drugs.
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